06/30/2024
Thanks to everyone again for following!
As promised, I'm going to kick off the page by sharing some information and analysis concerning the exciting impeding rescheduling of cannabis from Schedule 1 to Schedule 3. Hopefully this will interest both our cannabis and non-cannabis friends.
Let's look at Scheduling itself and the Rescheduling Process.
The potential rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA) has garnered significant attention from policymakers, healthcare professionals, industry stakeholders, and the general public.
Understanding Scheduling
The CSA of 1970 categorizes drugs into five schedules based on their potential for abuse, medical utility, and safety:
Schedule I: High potential for abuse, no accepted medical use (e.g., he**in, L*D, cannabis).
Schedule II: High potential for abuse, accepted medical uses with severe restrictions (e.g., co***ne, methamphetamine).
Schedule III: Moderate to low potential for physical and psychological dependence, accepted medical uses (e.g., anabolic steroids, ketamine).
Schedule IV: Low potential for abuse and dependence, accepted medical uses (e.g., Xanax, Va**um).
Schedule V: Lower potential for abuse than Schedule IV, accepted medical uses (e.g., cough preparations with codeine).
(Of course, it remains baffling that even at Schedule 3, cannabis will be regarded as having a higher potential for abuse and higher safety risk than Xanax and Va**um.)
Understanding the Rescheduling Process:
Rescheduling a substance involves a multi-step process:
Petition Submission:
Interested parties, including patients, advocacy groups, or government agencies, can submit a petition to reschedule a drug.
FDA Review:
The FDA conducts a scientific and medical evaluation, resulting in an Eight-Factor Analysis assessing abuse potential, medical use, and safety.
HHS Recommendation:
The Department of Health and Human Services (HHS) makes a recommendation to the DEA based on the FDA's analysis.
DEA Review:
The DEA evaluates the HHS recommendation, considers public comments, and may conduct its own research.
Rulemaking Process:
If the DEA agrees with the rescheduling petition, it initiates a rulemaking process, which includes publishing a proposed rule, soliciting public comments, and issuing a final rule.
Rescheduling Cannabis:
The rescheduling process is influenced by political, administrative, and social factors. Political support, particularly from the current administration and key legislators, played a crucial role. President Biden's directive in October 2022 to review cannabis scheduling has accelerated the process.
In October 2023, a bipartisan group of congressmembers urged the DEA to consider descheduling ma*****na entirely. By December, HHS released a comprehensive document supporting the rescheduling of cannabis, leading to the DEA's formal review in early 2024. The DEA is expected to finalize its decision by late summer 2024, although the exact timing remains uncertain due to potential administrative and political delays.
Stay tuned this week for more info and significant analysis of the legal, political, regulatory, banking, taxation, federal oversight and interstate commerce implications of rescheduling.
Questions, comments or input always welcome!
